Notably, treatment with an EZH2 inhibitor restores immune cell infiltration and inhibits tumor growth in NSD1-mutant models, highlighting a druggable chromatin crosstalk with potential therapeutic relevance [39]. Here, EZH2 is linked to neoplasm.